Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ: IPA )

0.5700 -0.0100 (-1.72%)
Streaming Delayed Price Updated: 12:47 PM EST, Jan 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,551,107
Open 0.5700
Bid (Size) 0.5600 (273)
Ask (Size) 0.5758 (2)
Prev. Close 0.5800
Today's Range 0.5590 - 0.6600
52wk Range 0.3248 - 2.600
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
What's Going On With ImmunoPrecise Antibodies Stock Wednesday?
Immunoprecise shares closed higher on Wednesday after the company announced it developed a new class of GLP-1 therapies. 
Via Benzinga

Performance

YTD
+26.67%
+26.67%
1 Month
+39.02%
+39.02%
3 Month
-1.01%
-1.01%
6 Month
-31.33%
-31.33%
1 Year
-65.45%
-65.45%

More News

Read More
Trump’s “Stargate AI” Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO
Via AB Newswire
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
Via Benzinga
Exposures Fossil Fuels
ImmunoPrecise Antibodies: Q2 Earnings Insights
Via Benzinga
A Preview Of ImmunoPrecise Antibodies's Earnings
Via Benzinga
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings
Via Benzinga
US Stocks Higher; Netflix Profit Beats Estimates
Via Benzinga
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA Announces Resignation of Chief Financial Officer
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Present at The Microcap Conference 2025
Via ACCESSWIRE
IPA to Present at The Microcap Conference 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Earnings Scheduled For December 10, 2024
Via Benzinga
IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
Via AB Newswire
Topics Electric Vehicles
Exposures Electric Vehicles Product Safety
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.